Loading...
XNAS
MLAB
Market cap504mUSD
Jul 09, Last price  
95.39USD
1D
4.41%
1Q
-0.47%
Jan 2017
-22.29%
Name

Mesa Laboratories Inc

Chart & Performance

D1W1MN
XNAS:MLAB chart
P/E
78.52
P/S
2.12
EPS
1.21
Div Yield, %
0.70%
Shrs. gr., 5y
1.66%
Rev. gr., 5y
13.22%
Revenues
249m
+3.38%
17,242,00019,558,00021,536,00021,929,00032,826,00039,616,00046,435,00052,724,00071,330,00084,659,00093,665,00096,179,000103,135,000117,687,000133,937,000184,335,000219,080,000216,187,000240,978,000249,130,000
Net income
7m
P
3,958,0004,610,0004,790,0004,769,0006,183,0007,919,0008,450,0009,000,0009,583,00011,169,00011,183,000-2,962,0007,484,0001,778,0003,274,0001,871,000930,000-254,246,000-1,974,0006,712,000
CFO
43m
-8.50%
4,032,0004,616,0005,075,0005,980,0008,873,00012,489,00011,402,00012,373,00010,816,00016,903,0007,750,00024,814,00030,554,00026,559,00037,073,00039,223,00027,983,00044,133,00046,808,00042,831,000
Dividend
Feb 27, 20260.16 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
IPO date
Feb 29, 1984
Employees
698
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT